Synthetic CRF 1-41 in a dose of 1 mcglkg was administered i.v. Plasma cortisol (CO) and ACTH were determined before and at 30, 60, 90 & 120 min. Fourteen children ( 1 2~, 2F 12t4.8 yrs) were investigated including 2 normal controls, 6 with IGHD and 6 with MPHD. According to the peak plasma CO during ITT the subjects were classified into 2 groups: Gr. A -intact hypothalamic-pi- 2 CRF DeE.
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4.6; 11.0 8.9; 25.0 63; 159 The CRF test made it possible to distinguish between a pituitary lesion (ACTH def.) and a hypothalamic detect (CRF def.). There was also a good correlation between the CRF, GH-RH and TRH tests in the same patients. Jt is concluded that the CRF test is a useful addition to the diagnostic endocrine armamentarium. These ~u l t s slggest that conventrod stemid/azothioprine immuncsuppres;ion may povide a less toxic alternative to Cyclcsprin i n the spedfic therapy d IDD.
X X T H E R A P Y F O R INSULIN DEPENDENT IlIABETES WD

GLUCOSE AND INSULIN MODULATE BRAIN OPIATE RECEPTORS.
89 Geor?e A.Werther and Annette Hoqq. Royal Children's Hospltal Dept.of Endocrinology, Melbourne, Australia. Feeding inhibition by the opiate antagonist naloxone is enhanced in diabetes and blunted by hypoglycaemia. The relative roles of glucose and insulin in these phenomena remain unclear. We investigated possible regulation of the opiate receptor by glucose and/or insulln by examining in vitro effects of glucose(5mM or 10mM) or insulin(luM), on tritiated naloxone binding to rat brain membranes. In whole brain membranes, glucose 5mM and lOmM increased 3-H-naloxone binding by lo+/-4%(n=4) and 38+/-9%(n=3). Insulin increased 3-H-naloxone binding by 27+/-3%(n=5). In hypothalamus, rich in opiate receptors, glucose(l0mM) and insulin(1uM) increased opiate binding by 17+/-3%(n=4) and 29+/-11%(n=3) respectively. Insulin was maximally effective at 0.2nM, enhancing binding by 57%. Glucose and insulin both enhanced the average affinity (Kd) for naloxone binding: control 0.76nM; glucose(l0mM) 0.38nM; insulin(luM)O.32nM. Anti-insulin receptor antibody and insulin analogue D-a1a.D-asp-insulin both mimicked the insulin effect, while proinsulin was weakly effective; hGH and IGF did not effect opiate binding. Modest in vivo modulation was demonstrated following intra-ventricular infusion of lOmM glucose, luM insulin, or artificial CSF for 6 days: Binding of 3-H-naloxone to hypothalamus was enhanced by 11+/-6% following glucose infusion (n=3) and 14+/-13% following insulin infusion (n=3). Conclusion: Glucose and insulin enhance naloxone binding to brain receptors. The mechanism involves an affinity increase of opiate receptors; insulin acts via its own receptor. These findings suggest that Althouqh considerable evidence suoports the role of EGF as a modulator-of developmental processes', data from adult humans are limited due to the lack of reliable measurement methods. There is no information from infants or children. We developed and characterized a homologous RIA system to implement clinical hEGF studies. Antibodies were raised in NZW rabbits against highly purified Chiron h-EGF. The same preparation was used as standard and radioiodinated with chloramine T. The antibody (1.5~105 final dilution) was incubated for 48 h at 7 ' C with standard and samples. Radiolabeled hEGF was added at 24 h and bound-free separation was performed by combined 2nd antibody and 5% polyethylene glycol. Sensitivity of the method is 30 pg; there is no crossreaction with insulin, placental NGF extract, IGF-I, IGF-I1 or renin up to levels of 100 ng. Within and across assay variations were 7.9 and 12.3%, respectively. Human EGF measured in urine of term newborns expressed in ng/mg of creatinine were 9.9'3.6
(xiSD) at 0 h and 3.9'1.8 at 24 h after birth (p<0.05). These values were lower than levels in normal boys and girls 6-8 In poorly controlled insulin-dependent diabetes, serum Sm-C concentrations are low despite high levels of growth hormone (GH), suqgesting GH resistance. Wether this resistance might be due to receptor or post-receptor defects remains however unclear. Therefore, the number and affinity constant of liver bovine GH binding sites and the serum Sm-C concentrations, 24 h after injection of graded doses of GH, were determined in hypophysectomized rats injected with saline (controls) or with 40 mg of streptozotocin/kg BW (diabetics). After one week of diabetes there were no significant changes in the affinity constants (diabetics : 0.68 ' 0.04 x lo9M-' vs controls : 0.92 ' 0.07 x 10'~-' : mean ' SE; n=8; P < 0. I ) or the numbers of GH bindinq sites (diabetics : 1.10 0.12 pmol/mg DNA vs controls : 1.26 -+ 0.15 prnol/mg DNA: P < 0.5). Despite the absence of alterations in GH binding, the maximal serum Sm-C response wasseverely blunted in the diabetics (2.02 t 0.32 U/ml) when compared to controls (17.41 ' 2.69 U/ml; P < 0.01). The sensitivity (ie ED50) however was the same for control and diabetics rats. These results strongly suggest that the CH resistant state in poorly controlled insulin-dependent diabetes is due to a ~o s treceptor defect.
insulin and glucose in the brain may play a role in modulating opiate receptors and their actlons.
